In a phase I/II clinical trial, elderly patients with MDS/AML, de novo AML and refractory high risk MDS were infused with haploidentical NK cells without IL-2 intake after administering less intense lymphodepleting (LD) regimen [9]. The gene discussed is IL2; the disease is myelodysplastic syndrome.